<DOC>
	<DOCNO>NCT01952392</DOCNO>
	<brief_summary>Prevention cardiovascular event antiplatelet agent acute coronary syndrome</brief_summary>
	<brief_title>Prevention Cardiovascular Events Antiplatelet Agents After Acute Coronary Syndrome</brief_title>
	<detailed_description>AReMIS ( Antiplatelet Recurrent Myocardial Infarction Study ) To compare relative risk new myocardial infarction ( recurrent myocardial infarction 'rMI ' ) patient history acute coronary syndrome ( 'ACS ' : unstable angina myocardial infarction ) , use ticagrelor , clopidogrel prasugrel ( applicable ) none treatment , aspirin consider covariate .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<criteria>Patients age 18 year , gender , acute coronary syndrome ( ACS ) , agree participate able respond interview French and/or provide detail alternative replier ( proxy ) necessary . No Exclusion Criteria .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Effectiveness study</keyword>
	<keyword>Acute coronary Syndrome</keyword>
	<keyword>Real-life</keyword>
	<keyword>France</keyword>
</DOC>